Available data suggest it can reduce fat mass substantially, while the proportion of lean-mass loss relative to total weight loss appears similar to other obesity treatments
lower per-mg pricing on most vendor pages compared with the 12.5/2.5 vial
We supply to about 2000 patients a month indirectly or directly and have been seen MoM growth which is decent , however there was a lot of frontloading of stocks by generic players and that correction is happening.
Meanwhile a Mercer study found that among employers with 500 or more employees, 6% dropped weight loss coverage in 2026 , and another 5% are planning or considering dropping it for 2027
In lieu of states expanding coverage, states that are committed to retaining coverage are looking at mechanisms to better control costs
[9] Patients currently taking tirzepatide should consult their healthcare provider before adding any supplement regimen, including NAD+ precursors